For the quarter ending 2025-09-30, CDTX had -$216,925K decrease in cash & cash equivalents over the period. -$40,615K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -83,233 | -49,198 |
| Stock-based compensation expense | 3,171 | 4,696 |
| Non-cash operating lease expense | 326 | 619 |
| Loss on assignment of finance lease | 0 | 158 |
| Depreciation and amortization | 28 | 63 |
| Amortization of finance lease right-of-use asset | 0 | 13 |
| Non-cash interest expense | 0 | 7 |
| Gain on disposal of property and equipment | 0 | 48 |
| Accretion of discounts, net of amortization of premiums, on available-for-sale investments | 166 | - |
| Reversal due to settlement of indirect tax liabilities | 0 | -9,445 |
| Loss on disposal of discontinued operations | 0 | 0 |
| Amortization of costs to obtain a contract with a customer | 0 | 0 |
| Accounts receivable | 2 | 165 |
| Inventory | 0 | 0 |
| Prepaid expenses, other current assets, and other assets | 24,971 | 206 |
| Accounts payable and accrued liabilities | 63,564 | -4,819 |
| Accrued indirect tax liabilities | 138 | -1,665 |
| Accrued compensation and benefits | 879 | -2,252 |
| Contract liabilities | 0 | 0 |
| Operating lease liabilities | -349 | -669 |
| Net cash used in operating activities | -40,615 | -62,911 |
| Purchases of available-for-sale investments | 176,470 | - |
| Proceeds from sales of property and equipment | 0 | 185 |
| Purchases of property and equipment | 0 | 0 |
| Net cash used in investing activities | -176,470 | 185 |
| Proceeds from underwritten public offering, net of issuance costs | -1,215 | 378,125 |
| Proceeds from at-the-market offering of common stock, net of issuance costs | -5 | 4,126 |
| Proceeds from exercise of stock options | 1,517 | 1,124 |
| Proceeds from private placement, net of issuance costs | 0 | 0 |
| Deferred financing costs | - | 137 |
| Payment of finance lease liabilities | 0 | 50 |
| Payment for shares withheld to fund payroll taxes | 0 | 0 |
| Net cash provided by financing activities | 160 | 383,462 |
| Net increase in cash, cash equivalents and restricted cash | -216,925 | 320,736 |
| Cash and cash equivalents at beginning of period | 196,177 | - |
| Cash and cash equivalents at end of period | 299,988 | - |
Cidara Therapeutics, Inc. (CDTX)
Cidara Therapeutics, Inc. (CDTX)